'Gatekeepers' Of Breast Cancer Transition To Invasive Disease Identified By Scientists

Main Category: Breast Cancer
Also Included In: Biology / Biochemistry
Article Date: 06 May 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Scientists have made a significant discovery that clarifies a previously poorly understood key event in the progression of breast cancer. The research, published by Cell Press in the May issue of the journal Cancer Cell, highlights the importance of the microenvironment in regulating breast tumor progression and suggests that it may be highly beneficial to consider therapies that do not focus solely on the tumor cells but are also targeted to the surrounding tissues.

Progression of breast cancer begins with abnormal epithelial proliferation that progresses into localized carcinoma, called ductal carcinoma in situ (DCIS); invasive carcinoma; and eventually, metastatic disease. DCIS is believed to be a precursor to invasive ductal carcinoma, but comprehensive molecular profiling studies comparing DCIS and invasive ductal carcinomas have not yielded tumor-stage-specific genetic signatures. "These studies have focused mainly on the tumor epithelial cells and have not explored the role of the microenvironment in tumor expression," says lead study author Dr. Kornelia Polyak from the Dana-Farber Cancer Institute in Boston.

Dr. Polyak and colleagues explored the involvement of the microenvironment in tumor progression by examining myoepithelial cells, which are known to play a critical role in mammary gland development and to have negative effects on tumor cell growth and invasion. To study the interactions between breast cancer cells and myoepithelial cells, the researchers used a human model of breast tumor progression called MCFDCIS, which forms DCIS-like lesions that spontaneously progress to invasive tumors, a pathology that closely resembles human disease.

Using this model, the researchers observed that normal myoepithelial cells suppress tumor growth and invasion in the absence of detectable genetic changes in the tumor epithelial cells. They went on to identify an intricate network involving TGFb, Hedgehog, cell adhesion, and p63 that appears to play a critical role in myoepithelial cell differentiation. Perturbation of key mediators of these signaling pathways led to a loss of myoepithelial cells and a progression to invasion.

"Here, we show that a key event of tumor progression is the disappearance of the myoepithelial cell layer due to defective myoepithelial cell differentiation regulated by intrinsic and microenvironment signals. Thus, myoepithelial cells can be considered gatekeepers of the in situ to invasive carcinoma transition; understanding the pathways that regulate their differentiation may open new venues for cancer therapy and prevention," offers Dr. Polyak.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

The researchers include Min Hu and Jun Yao of Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA; Danielle K. Carroll of Harvard Medical School in Boston, MA; Stanislawa Weremowicz of Brigham and Women's Hospital and Harvard Medical School in Boston, MA; Haiyan Chen of Dana-Farber Cancer Institute and Harvard School of Public Health in Boston, MA; Daniel Carrasco of Dana-Farber Cancer Institute in Boston, MA; Andrea Richardson of Brigham and Women's Hospital and Harvard Medical School in Boston, MA; Shelia Violette of Biogen-Idec in Cambridge, MA; Tatiana Nikolskaya and Yuri Nikolsky of GeneGo, Inc. in St. Joseph, MI; Erica L. Bauerlein and William C. Hahn of Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA; Rebecca S. Gelman of Dana-Farber Cancer Institute and Harvard School of Public Health in Boston, MA; Craig Allred of Washington University School of Medicine in St. Louis, MO; Mina J. Bissell of Lawrence Berkeley National Laboratory in Berkeley, CA; Stuart Schnitt of Harvard Medical School and Beth-Israel Deaconess Medical Center in Boston, MA; and Kornelia Polyak of Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA.

This work was supported in part by NIH, DOD, and ACS grants, a Susan G. Komen Foundation fellowship, Biogen-Idec., and Novartis Pharmaceuticals, Inc.

Hu et al.: "Regulation of In Situ to Invasive Breast Carcinoma Transition." Publishing in Cancer Cell 13, 394-406, May 2008. DOI 10.1016/j.ccr.2008.03.007 http://www.cancercell.org/

Source: Cathleen Genova
Cell Press